PCAS: NET SALES AS OF SEPTEMBER 30, 2022
03 November 2022 - 6:00PM
PCAS: NET SALES AS OF SEPTEMBER 30, 2022
Ecully, November 3, 2022
NET SALES AS OF SEPTEMBER 30,
2022
PCAS (Euronext Paris: PCA), a
specialist in developing and producing complex molecules for life
sciences and innovative technologies, has announced the publication
of its consolidated net sales as of September 30, 2022.
The PCAS Group has generated consolidated net
sales of €156.1 million as of September 30, 2022, a 9.6%
increase compared to the same period during the previous financial
year (+7.1% at constant exchange rates).
|
In millions of euros |
|
2022 |
|
2021 |
|
% change |
|
2022 At a constant exchange rate |
|
% change |
|
|
|
|
|
|
|
|
|
|
|
|
| Net sales
as of 30 September |
|
156.1 |
|
142.4 |
|
9.6% |
|
152.5 |
|
7.1% |
| Pharmaceutical
Synthesis |
|
94.3 |
|
93.2 |
|
1.3% |
|
92.7 |
|
-0.5% |
|
Fine Specialty Chemicals |
|
61.8 |
|
49.2 |
|
25.4% |
|
59.8 |
|
21.4% |
Pharmaceutical SynthesisThe
Pharmaceutical Synthesis business generated sales of €94.3 million,
a 1.3% increase compared to 2021 (a 0.5% decrease at a constant
exchange rate). Third-quarter revenue was up sharply compared to
2021, driven by the sales of Estetrol to Mithra, a favorable
EUR/USD exchange rate and the effect of price increases implemented
in the past few months to offset the very significant rise in raw
material and energy costs. Momentum remained very strong at the
Turku site, while activity linked to R&D and intermediates was
significantly lower compared to 2021.
Fine Specialty Chemicals
Net sales of Fine Specialty Chemicals totaled
€61.8 million, a 25.4% increase compared to 2021 (+21.4% at a
constant exchange rate). Activity held up well in the third
quarter, with continued strong demand for Electronics and
Cosmetics, and positive trends in Lubricants and Fine Chemicals.
The rise in the costs of raw materials and energy were passed on
downstream and contributed to the growth in net sales.
OutlookThe PCAS Group will
still generate a significant loss in 2022 due to a level of
activity which remains insufficient at several Pharmaceutical
Synthesis sites to cover the level of fixed costs and by inventory
depreciations linked to non-compliant products.
All the PCAS Group teams, with the support of
its majority shareholder Seqens for the financing of its activities
and its development, remain fully committed to returning to
positive results in 2023, helped by gradual growth in Estetrol
volumes for Mithra.
NEXT FINANCIAL DISCLOSURE:
2022 Net sales, February 3, 2023
ABOUT PCAS
PCAS specializes in the development and
production of complex molecules for life sciences and innovative
technologies. With about 12% of its net sales earmarked for R&D
and a large international footprint, PCAS is the preferred
industrial partner for market-leading major global groups. Boasting
especially high standards, the company offers a growing range of
proprietary products and solutions in leading-edge segments. PCAS
generated net sales of €187.0 million in 2021 and employs nearly
1100 people in six countries.To find out more about PCAS:
www.pcas.com
|
PCAS |
NewCap |
|
Philippe Clavel / Eric Moissenot |
Emmanuel Huynh / Louis-Victor Delouvrier
NewCapFinancial communication and investor
relations |
|
Tel.: +33 1 69 79 60 00www.pcas.com |
Tel.: +33 1 44 71 98 53pcas@newcap.eu |
| |
|
- PCAS _PR_sales as of September 30 2022_ENG
Pcas (LSE:0NF7)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Pcas (LSE:0NF7)
Historical Stock Chart
Von Dez 2023 bis Dez 2024
